Research programme: monoclonal antibodies - MABLife

Drug Profile

Research programme: monoclonal antibodies - MABLife

Alternative Names: 111In-AMB8LK; 90Y-AMBLK; AMB8LK; Anti-CD44 (chimeric gamma-1) monoclonal antibodies - MABLife; Anti-CD71 (chimeric gamma-1) monoclonal antibodies - MABLife; Hyaloxan; Hyaluximab (chimeric gamma-4 anti-CD44 monoclonal antibody); MAT-302 (chimeric anti-CD160 monoclonal antibody) - MABLife; MAT-303 (chimeric anti-CD160 monoclonal antibody) - MABLife; MAT-304 (chimeric anti-CD5 monoclonal antibody) - MABLife; MAT-401

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator MAT Biopharma
  • Developer Immune Pharmaceuticals Ltd; MABLife
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors; CD44 antigen inhibitors; CD71 antigen inhibitors; Iron-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Aspergillosis; Autoimmune disorders; Eye disorders; Liver cancer; Pancreatic cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Aspergillosis in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top